Healthcare Sector in Focus: Complementary Research on Alexion, OraSure, Lannett, BioTelemetry and Versartis

NEW YORK, May 12, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.  

Moments ago, Analysts Review released new research updates concerning several important developing situations including Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), OraSure Technologies, Inc. (NASDAQ: OSUR), Lannett Company, Inc. (NYSE: LCI), BioTelemetry, Inc. (NASDAQ: BEAT), and Versartis, Inc. (NASDAQ: VSAR). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.    

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

ALXN Research Report: ( http://get.analystsreview.com/pdf/?c=Alexion&d=12-May-2015&s=ALXN ),

OSUR Research Report: ( http://get.analystsreview.com/pdf/?c=OraSure&d=12-May-2015&s=OSUR ),

LCI Research Report: ( http://get.analystsreview.com/pdf/?c=Lannett&d=12-May-2015&s=LCI ),

BEAT Research Report: ( http://get.analystsreview.com/pdf/?c=BioTelemetry&d=12-May-2015&s=BEAT ),

VSAR Research Report: ( http://get.analystsreview.com/pdf/?c=Versartis&d=12-May-2015&s=VSAR ).

============

--

Analyst Update: Financial Results  and Update on Clinical Programs

The U.S. markets ended lower on Monday as the concern over Greece's precarious financial condition and China's slowing growth weighed on the investor sentiment. The energy index saw a sharp sell off on the back of weak oil prices. The Dow Jones Industrial Average fell by 85.94 points or 0.47% to close the day at 18,105.17. The NASDAQ and S&P 500 ended the day at 4,993.57 and 2,105.33, respectively, down by 0.2% and 0.51%, respectively, for the day. The European markets too ended the day in the red on Greece debt fears. The FTSE 100 was down 0.24%, DAX lost 0.31%, and CAC 40 plunged 1.23%. However, Asian markets (excluding Australia), traded higher as investors cheered China's latest cut in interest rates to boost its slowing economy.

Alexion Pharmaceuticals, Inc. announced its financial results for the first quarter of 2015 on April 23, 2015. The Company reported net product sales of Soliris® (eculizumab) of $600.3 million for Q1 FY15 versus reported figures of $566.6 million in Q1 FY14. According to the announcement, the Company attributes this increase in revenue to steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) commencing Soliris treatment across the Company's 50-country global platform.

On May 6, 2015, OraSure Technologies, Inc. announced its financial results for Q1 FY15. The Company reported consolidated net revenues of $27.1 million for the reported period, which was an increase of 15% on a Y-o-Y basis. Consolidated net income for Q1 FY15 was $113,000, which compares to a net loss of $5.6 million for Q1 FY14.

Lannett Company, Inc. announced financial results for third quarter fiscal 2015 on May 6, 2015. The Company reported net sales of $99.4 million for the quarter, which reflected a rise of 24% over the $80 million figure reported by the Company in Q3 FY14. Lannett reported that its operating income increased by 51% to $54.3 million on a Y-o-Y basis.

On May 6, 2015, BioTelemetry, Inc. announced its financial results for the first quarter of 2015. The Company reported revenues of $43.4 million for Q1 FY15 compared to $37.2 million for Q1 FY14, a growth of 17%. The Company attributes half of the increase in revenue to the full quarter impact of the Mednet and BMS acquisitions that occurred in the first and second quarters of 2014, respectively.

On May 6, 2015, Versartis, Inc. announced an update on its clinical programs for VRS-317. According to the announcement, the Company initiated its global Phase 3 registration trial, VELOCITY, in GHD children in January 2015. The US Food and Drug Administration (FDA) recently requested additional bioanalytical data and placed the VRS-317 Investigational New Drug Application (IND) on a partial clinical hold (PCH) pending receipt of those data.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review